View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
July 4, 2019

Calithera to study telaglenastat with Pfizer’s palbociclib

Calithera Biosciences has commenced a Phase I/II clinical trial of its telaglenastat (CB-839) in combination with Pfizer’s palbociclib (Ibrance) for the treatment of cancer.

Calithera Biosciences has commenced a Phase I/II clinical trial of its telaglenastat (CB-839) in combination with Pfizer’s palbociclib (Ibrance) for the treatment of cancer.

Telaglenastat is a glutaminase inhibitor, while palbociclib inhibits cyclin-dependent kinase (CDK) 4/6.

Genetic alterations, including KRAS mutations, are known to lead to increased glutamine metabolism in cancer cells.

Preclinical studies in KRAS-mutated cancer models demonstrated that telaglenastat has synergistic anti-tumour effects when combined with CDK4/6 inhibitors. This synergistic approach was observed to boost cell cycle arrest and block cancer cell proliferation.

The open-label Phase I/II trial will assess the safety and anti-tumour activity of the combination in locally advanced/metastatic KRAS-mutated colorectal cancer (CRC) patients.

The study will also involve participants with KRAS-mutated non-small cell lung cancer (NSCLC). Patients who are refractory or intolerant to standard therapies will be enrolled.

The first subject in the trial has already been treated with a combination of telaglenastat and palbociclib.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena